Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP.

William J HulmeElsie M F HorneEdward P K ParkerRuth H KeoghElizabeth J WilliamsonVenexia WalkerTom M PalmerHelen J CurtisAlex J WalkerColm D AndrewsAmir MehrkarJessica MorleyBrian MacKennaSebastian C J BaconBen GoldacreMiguel A HernánJonathan A C Sterne

Published in: BMJ (Clinical research ed.) (2023)

This matched observational study of adults estimated a modest benefit of booster vaccination with mRNA-1273 compared with BNT162b2 in preventing positive SARS-CoV-2 tests and hospital admission with covid-19 20 weeks after vaccination, during a period of delta followed by omicron variant dominance.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
emergency department
binding protein
healthcare
adverse drug
acute care